<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504477</url>
  </required_header>
  <id_info>
    <org_study_id>2011-033</org_study_id>
    <secondary_id>X05374</secondary_id>
    <nct_id>NCT01504477</nct_id>
  </id_info>
  <brief_title>Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase I/II Clinical Trial of the Anti-EGFR Monoclonal Antibody, Panitumumab, and the Proteosomal Inhibitor, Bortezomib, in Patients With Advanced, Refractory KRAS Wild-Type Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Panitumumab plus bortezomib for colon cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is for patients with colon cancer that cannot be fully removed by surgery and has
      come back after or not responded to standard chemotherapy treatment.

      Subjects will be enrolled to either the first part of the study (Phase I) or the second part
      of the study (Phase II). Phase I will be completed before Phase II will start. The purpose of
      the Phase I part is to find the highest dose of bortezomib that can be given with panitumumab
      without causing severe side effects. The purpose of the Phase II part is to test the effects
      the two drugs have on subjects with colorectal cancer.

      Panitumumab is a drug that targets a protein important for the growth of cancer cells known
      as EGFR. By blocking the activity of the protein, panitumumab can block cancer cell growth
      and even lead to their death. Panitumumab is given intravenously once every two weeks.
      Panitumumab is approved by the FDA for patients with colorectal cancer.

      Bortezomib is a drug that targets a part of the cancer cell known as the proteosome. By
      inhibiting the proteosome, bortezomib can inhibit cancer cell growth and even lead to their
      death. Bortezomib is given intravenously, once a week, 3 out of every 4 weeks. Bortezomib is
      not FDA approved for the treatment of colorectal cancer.

      As part of this study the investigators will be taking biopsies of patients' tumors before
      any treatment, after starting with the panitumumab alone, and after receiving both the
      panitumumab and bortezomib. The investigators want to investigate what markers inside tumors
      may relate to how well these two medications work. These biopsies are required as part of the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual--unable to meet accrual goals
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>12 months</time_frame>
    <description>The maximum tolerated dose of bortezomib (to be used in combination with panitumumab)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>12 months</time_frame>
    <description>The maximum tolerated dose of panitumumab (to be used in combination with bortezomib)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Disease Control</measure>
    <time_frame>16 weeks</time_frame>
    <description>Stable disease after 2 cycles, partial response or complete response as determined by RECIST v1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of of Patients With a Complete or Partial Response</measure>
    <time_frame>16 weeks</time_frame>
    <description>Partial response plus complete response as per RECIST v1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Disease Control</measure>
    <time_frame>2 years</time_frame>
    <description>Time from study registration until progressive disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Combination of Panitumumab and Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV panitumumab and bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab and bortezomib</intervention_name>
    <description>Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
    <arm_group_label>Combination of Panitumumab and Bortezomib</arm_group_label>
    <other_name>Velcade</other_name>
    <other_name>Vectibix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven colorectal cancer with measurable or evaluable disease

          -  KRAS wild-type colorectal cancer

          -  Progression on, or intolerance of, or ineligibility for all standard therapies

          -  Progression on prior anti-EGFR therapy

          -  Lesion that is amenable to biopsy

          -  ECOG performance status 0-2

          -  LVEF &gt;/= institutional normal

          -  Corrected QT interval less then 500 milliseconds by EKG

          -  Grade 2 or less peripheral neuropathy

          -  Adequate hepatic, bone marrow, and renal function

          -  Partial thromboplastin time must be &lt;/= 1.5 x upper limit of institution's normal
             range and INR &lt; 1.5. Subjects on anticoagulants will be permitted to enroll as long as
             the INR is in the acceptable therapeutic range as determined by the investigator.

          -  Subjects with no brain metastases or a history of previously treated brain metastases
             who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior
             to enrollment and have a baseline MRI that shows no evidence of active intracranial
             disease and have not had treatment with steroids within 1 week of study enrollment.

          -  Life expectancy &gt; 12 weeks

          -  Subject is capable of understanding and complying with parameters of the protocol and
             able to sign and date the informed consent form.

        Exclusion Criteria:

          -  CNS metastases which do not meet the criteria above

          -  Prior cancer chemotherapy, radiation therapy, or any investigational agent within
             three weeks before starting therapy

          -  Active severe infection or known chronic infection with HIV or hepatitis B virus

          -  Cardiovascular disease problems including unstable angina, therapy for
             life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or
             congestive heart failure within the last 6 months

          -  Peripheral neuropathy &gt;/= Grade 2 at baseline or peripheral neuropathy &gt;/= Grade 1
             with neuropathic pain

          -  Life-threatening visceral disease or other severe concurrent disease

          -  Female subject is pregnant or lactating

          -  Diagnosed or treated for another malignancy within 3 years of enrollment with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low risk prostate cancer after curative therapy

          -  Patient has hypersensitivity to bortezomib, boron, or mannitol

          -  Clinically significant and uncontrolled major medical condition(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Pishvaian, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <results_first_submitted>May 6, 2018</results_first_submitted>
  <results_first_submitted_qc>March 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2020</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>Kras wild type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan for this</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination of Panitumumab and Bortezomib</title>
          <description>IV panitumumab and bortezomib
Panitumumab and bortezomib: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination of Panitumumab and Bortezomib</title>
          <description>IV panitumumab and bortezomib
Panitumumab and bortezomib: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.83" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose</title>
        <description>The maximum tolerated dose of bortezomib (to be used in combination with panitumumab)</description>
        <time_frame>12 months</time_frame>
        <population>The maximally tolerated dose of bortezomib weekly to be used in combination with with Panitumumab every 2 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Combination of Panitumumab and Bortezomib</title>
            <description>IV panitumumab and bortezomib
Panitumumab and bortezomib: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose</title>
          <description>The maximum tolerated dose of bortezomib (to be used in combination with panitumumab)</description>
          <population>The maximally tolerated dose of bortezomib weekly to be used in combination with with Panitumumab every 2 weeks</population>
          <units>mg/m2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Disease Control</title>
        <description>Stable disease after 2 cycles, partial response or complete response as determined by RECIST v1.0</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Panitumumab and Bortezomib</title>
            <description>IV panitumumab and bortezomib
Panitumumab and bortezomib: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Disease Control</title>
          <description>Stable disease after 2 cycles, partial response or complete response as determined by RECIST v1.0</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of of Patients With a Complete or Partial Response</title>
        <description>Partial response plus complete response as per RECIST v1.0</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Panitumumab and Bortezomib</title>
            <description>IV panitumumab and bortezomib
Panitumumab and bortezomib: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of of Patients With a Complete or Partial Response</title>
          <description>Partial response plus complete response as per RECIST v1.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Disease Control</title>
        <description>Time from study registration until progressive disease</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Panitumumab and Bortezomib</title>
            <description>IV panitumumab and bortezomib
Panitumumab and bortezomib: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Disease Control</title>
          <description>Time from study registration until progressive disease</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="8" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose</title>
        <description>The maximum tolerated dose of panitumumab (to be used in combination with bortezomib)</description>
        <time_frame>12 months</time_frame>
        <population>The maximum tolerated dose of panitumumab (to be used in combination with bortezomib)</population>
        <group_list>
          <group group_id="O1">
            <title>Combination of Panitumumab and Bortezomib</title>
            <description>IV panitumumab and bortezomib
Panitumumab and bortezomib: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose</title>
          <description>The maximum tolerated dose of panitumumab (to be used in combination with bortezomib)</description>
          <population>The maximum tolerated dose of panitumumab (to be used in combination with bortezomib)</population>
          <units>mg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combination of Panitumumab and Bortezomib</title>
          <description>IV panitumumab and bortezomib
Panitumumab and bortezomib: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrolyte</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Pishvaian</name_or_title>
      <organization>Georgetown University</organization>
      <phone>202-444-2223</phone>
      <email>pishvaim@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

